Stoke Therapeutics Company Leadership
| STOK Stock | USD 8.15 0.18 2.16% |
Stoke Therapeutics employs about 13 people. The company is managed by 13 executives with a total tenure of roughly 31 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Inspection of Stoke Therapeutics' management performance can provide insight into the company performance.
Stoke |
Stoke Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2535) % which means that it has lost $0.2535 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.458) %, meaning that it created substantial loss on money invested by shareholders. Stoke Therapeutics' management efficiency ratios could be used to measure how well Stoke Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Stoke Therapeutics Workforce Comparison
Stoke Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,616. Stoke Therapeutics maintains roughly 13.0 in number of employees contributing less than 1% to equities under Health Care industry.
The company has Profit Margin (PM) of (2.43) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.6) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.6. Stoke Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Stoke Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Stoke Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Stoke Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Stoke Therapeutics Notable Stakeholders
A Stoke Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Stoke Therapeutics often face trade-offs trying to please all of them. Stoke Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Stoke Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| CPA CPA | Chief Officer | Profile | |
| Jonathan JD | Corporate Counsel | Profile | |
| Shamim MS | Senior Officer | Profile | |
| Dawn Kalmar | Chief Officer | Profile | |
| Eric Olson | Chief Officer | Profile | |
| FACC MD | Chief Officer | Profile | |
| Joan Wood | Chief Officer | Profile | |
| Huw Nash | Chief Officer | Profile | |
| Isabel Aznarez | CoFounder Research | Profile | |
| Eric Rojas | Head Relations | Profile | |
| Thomas Leggett | Chief Officer | Profile | |
| Jason Hoitt | Chief Officer | Profile | |
| Adrian Krainer | Independent CoFounder | Profile |
About Stoke Therapeutics Management Performance
The success or failure of an entity such as Stoke Therapeutics often depends on how effective the management is. Stoke Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Stoke management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Stoke management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases in the United States. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. Stoke Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 102 people.
Stoke Therapeutics Workforce Analysis
Traditionally, organizations such as Stoke Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Stoke Therapeutics within its industry.Stoke Therapeutics Manpower Efficiency
Return on Stoke Therapeutics Manpower
| Revenue Per Employee | 2.8M | |
| Revenue Per Executive | 2.8M | |
| Net Loss Per Employee | 6.8M | |
| Net Loss Per Executive | 6.8M | |
| Working Capital Per Employee | 14.8M | |
| Working Capital Per Executive | 14.8M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stoke Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stoke Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Stoke Therapeutics is measured differently than its book value, which is the value of Stoke that is recorded on the company's balance sheet. Investors also form their own opinion of Stoke Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Stoke Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stoke Therapeutics' market value can be influenced by many factors that don't directly affect Stoke Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stoke Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.